Fucoidan Therapy Decreases the Proviral Load in Patients with Human T-Lymphotropic Virus Type-1-Associated Neurological Disease
Abstract
Background
Human T-lymphotropic virus type-1 (HTLV-1) is a human retrovirus that causes HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and adult T-cell leukaemia (ATL). A higher viral load in individuals with HTLV-1 infection increases their risk of developing HAM/TSP and ATL. Moreover, the high proviral load is associated with the clinical progression of HAM/TSP. Reduction of the number of HTLV-1-infected cells is therefore crucial for preventing and treating HTLV-1-associated diseases. Recently, fucoidan, a complex sulphated polysaccharide derived from marine seaweed, has been demonstrated to exert inhibitory effects on HTLV-1 infection in vitro. In this study, we examined the in vivo effects of fucoidan on HTLV-1 infection.
Methods
In this single-centre open-label trial, 13 patients with HAM/TSP were treated with 6 g fucoidan daily for 6–13 months. The HTLV-1 proviral DNA load and frequencies of HTLV-1-specific CD8+ T-cells, natural killer cells, invariant natural killer T-cells and dendritic cells in the peripheral blood were analysed. Furthermore, the in vitro inhibitory effect of fucoidan on cell-to-cell HTLV-1 infection was examined by using luciferase reporter cell assays.
Results
Fucoidan inhibited the cell-to-cell transmission of HTLV-1 in vitro. Furthermore, fucoidan therapy resulted in a 42.4% decrease in the HTLV-1 proviral load without affecting the host immune cells. During the treatment, no exacerbation was observed. Four patients with HAM/TSP developed diarrhoea, which improved immediately after stopping fucoidan administration.
Conclusions
Fucoidan is a new potential therapeutic agent for the prevention and treatment of HTLV-1-associated diseases.
References
1. de Thé G., Bomford R. An HTLV-I vaccine: why, how, for whom? AIDS Res Hum Retroviruses 1993; 9: 381–386.
2. Uchiyama T., Yodoi J., Sagawa K., Takatsuki K., Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood 1977; 50: 481–492.
3. Gessain A., Barin F., Vernant J.C.et al. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985; 2: 407–410.
4. Osame M., Usuku K., Izumo S.et al. HTLV-I associated myelopathy, a new clinical entity. Lancet 1986; 1: 1031–1032.
5. Nagai M., Usuku K., Matsumoto W.et al. Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. J Neurovirol 1998; 4: 586–593.
6. Nagai M., Yamano Y., Brennan M.B., Mora C.A., Jacobson S. Increased HTLV-I proviral load and preferential expansion of HTLV-I Tax -specific CD8+ T cells in cerebrospinal fluid from patients with HAM/TSP. Ann Neurol 2001; 50: 807–812.
7. Yamano Y., Nagai M., Brennan M.et al. Correlation of human T-cell lymphotropic virus type 1 (HTLV-1) mRNA with proviral DNA load, virus-specific CD8(+) T cells, and disease severity in HTLV-1-associated myelopathy (HAM/ TSP). Blood 2002; 99: 88–94.
8. Okayama A., Stuver S., Matsuoka M.et al. Role of HTLV-1 proviral DNA load and clonality in the development of adult T-cell leukemia/lymphoma in asymptomatic carriers. Int J Cancer 2004; 110: 621–625.
9. Mahony M.C., Oehninger S., Clark G.F.et al. Fucoidan inhibits the zona pellucid-induced acrosome reaction in human spermatozoa. Contraception 1991; 44: 657–665.
10. Baba M., Snoeck R., Pauwels R., de Clercq E. Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, and human immunodeficiency virus. Antimicrob Agents Chemother 1988; 32: 1742–1745.
11. Zacharopoulos V.R., Phillips D.M. Cell-mediated HTLV-1 infection of a cervix-derived epithelial cell line. Microb Pathog 1997; 23: 225–233.
12. Romanos M.T.V., Andrada-Serpa M.J., Mourao P.A.S.et al. A sulphated fucan from the Laminaria abyssalis inhibits the human T cell lymphotropic virus type 1- induced syncytium formation in HeLa cells. Antivir Chem Chemother 2002; 13: 219–221.
13. Haneji K., Matsuda T., Tomita M.et al. Fucoidan extracted from Cladosiphon okamuranus Tokida induces apoptosis of human T-cell leukemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells. Nutr Cancer 2005; 52: 189–201.
14. Yoshida A., Piroozmand A., Sakurai A.et al. Establishment of a biological assay system for human retroviral protease activity. Microbes Infect 2005; 7: 820–824.
15. Fukushima N., Nakamura T., Nishiura Y., Ida H., Aramaki T., Eguchi K. HTLV-I production based on activation of integrin/ ligand signaling in HTLV-I-infected T cell lines derived from HAM/TSP patients. Intervirology 2008; 51: 123–129.
16. Osame M. Review of WHO Kagoshima meeting and diagnostic guidelines for HAM/TSP. In Blattner W.A. (Editor). Human Retrovirology: HTLV. New York: Raven Press 1990; pp. 191–197.
17. Nakagawa M., Izumo S., Ijichi S.et al. HTLV-I associated myelopathy: analysis of 213 patients based on clinical features and laboratory findings. J Neurovirol 1995; 1: 50–61.
18. Nagai M., Kubota R., Greten T.F.et al. Increased activated human T cell lymphotropic virus type I (HTLV-I) Tax11-19-specific memory and effector CD8+ cells in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis: correlation with HTLV-I provirus load. J Infect Dis 2001; 183: 197–205.
19. Igakura T., Stinchcombe J.C., Goon P.K.et al. Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton. Science 2003; 299: 1713–1716.
20. Bangham C.R. HTLV-1 infection: role of CTL efficiency. Blood 2008; 112: 2176–2177.
21. Azakami K., Sato T., Araya N.et al. Severe loss of invariant NKT cells exhibiting anti-HTLV-1 activity in patients with HTLV-1-associated disorders. Blood 2009; 114: 3208–3215.
22. Bangham C.R., Osame M. Cellular immune response to HTLV-1. Oncogene 2005; 24: 6035–6046.
23. Oh U., Yamano Y., Mora C.A.et al. Interferon-beta1a therapy in human T-lymphotropic virus type I-associated neurologic disease. Ann Neurol 2005; 57: 526–534.
24. Nomoto M., Utatsu Y., Soejima Y., Osame M. Neopterin in cerebrospinal fluid: a useful marker for diagnosis of HTLV-I-associated myelopathy/tropical spastic paraparesis. Neurology 1991; 41: 457.
25. Takenouchi N., Yamano Y., Usuku K., Osame M., Izumo S. Usefulness of proviral load measurement for monitoring of disease activity in individual patients with human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis. J Neurovirol 2003; 9: 29–35.
26. Taylor G.P., Tosswill J.H., Matutes E.et al. Prospective study of HTLV-I infection in an initially asymptomatic cohort. J Acquir Immune Defic Syndr 1999; 22: 92–100.
27. Nose H., Saito M., Usuku K.et al. Clinical symptoms and the odds of human T-cell lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in healthy virus carriers: application of best-fit logistic regression equation based on host genotype, age, and provirus load. J Neurovirol 2006; 12: 171–177.
28. Yamano Y., Cohen C.J., Takenouchi N.et al. Increased expression of human T lymphocyte virus type I (HTLV-I) Tax11-19 peptide-human histocompatibility leukocyte antigen A*201 complexes on CD4+CD25+ T cells detected by peptide-specific, major histocompatibility complex-restricted antibodies in patients with HTLV-I-associated neurologic disease. J Exp Med 2004; 199: 1367–1377.
29. Yamano Y., Araya N., Sato T.et al. Abnormally high levels of virus-infected IFN-gamma+CCR4+CD4+CD25+ T cells in a retrovirus-associated neuroinflammatory disorder. PLoS ONE 2009; 4: e6517.
30. Saito M., Nakagawa M., Kaseda S.et al. Decreased human T lymphotropic virus type I (HTLV-I) provirus load and alteration in T cell phenotype after interferon-alpha therapy for HTLV-I-associated myelopathy/tropical spastic paraparesis. J Infect Dis 2004; 189: 29–40.
31. Nishiura Y., Nakamura T., Fukushima N.et al. Disulfide-mediated apoptosis of human T-lymphotropic virus type-I (HTLV-I)-infected cells in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis. Antivir Ther 2009; 14: 533–542.
32. Sonoda J., Koriyama C., Yamamoto S.et al. HTLV-1 provirus load in peripheral blood lymphocytes of HTLV-1 carriers is diminished by green tea drinking. Cancer Sci 2004; 95: 596–601.
33. Taylor G.P., Goon P., Furukawa Y.et al. Zidovudine plus lamivudine in human T-lymphotropic virus type-I-associated myelopathy: a randomised trial. Retrovirology 2006; 3: 63.
34. Li H.C., Yashiki S., Sonoda J.et al. Green tea polyphenols induce apoptosis in vitro in peripheral blood T lymphocytes of adult T-cell leukemia patients. Jpn J Cancer Res 2000; 91: 34–40.
Cite article
Cite article
Cite article
OR
Download to reference manager
If you have citation software installed, you can download article citation data to the citation manager of your choice
Information, rights and permissions
Information
Published In
Article first published online: January 1, 2011
Issue published: January 2011
Authors
Metrics and citations
Metrics
Article usage*
Total views and downloads: 118
*Article usage tracking started in December 2016
Articles citing this one
Receive email alerts when this article is cited
Web of Science: 0
Crossref: 41
-
HAM/TSP Pathogenesis: The Transmigration Activity of HTLV-1-Infected T...
-
Otoprotective Effects of Fucoidan Reduce Cisplatin-Induced Ototoxicity...
-
Seaweed sulfated polysaccharides and their medicinal properties
-
Oral Macrocystis pyrifera Fucoidan Administration Exhibits Anti-Inflam...
-
HTLV, a multi organ oncovirus
-
Protective effects of fucoidan against kidney diseases: Pharmacologica...
-
Gene Set Enrichment Analysis Reveals That Fucoidan Induces Type I IFN ...
-
Seaweeds and Their Products for the Health of Livestock
-
The Use of Oligo Fucoidan in Cancer Bearing Dogs Undergoing Chemothera...
-
Tea polyphenols improve the memory in aging ovariectomized rats by reg...
-
Marine algae as efficacious bioresources housing antimicrobial compoun...
-
Potential Antiviral Properties of Industrially Important Marine Algal ...
-
Brown Seaweed Food Supplementation: Effects on Allergy and Inflammatio...
-
Effects of Ingesting Fucoidan Derived from Cladosiphon okamuranus Toki...
-
The Therapeutic Potential of the Anticancer Activity of Fucoidan: Curr...
-
The anti-cancer effects of fucoidan: a review of both in vivo and in v...
-
Intestinal Microbiota and Immune Modulation in Zebrafish by Fucoidan F...
-
Marine-Derived Surface Active Agents: Health-Promoting Properties and ...
-
Fucoidan: Biological Activity in Liver Diseases
-
Activation of NK cells in male cancer survivors by fucoidan extracted ...
-
Evaluation of the Immunomodulatory Effects of Fucoidan Derived from Cl...
-
Fucoidan Promotes Apoptosis and Inhibits EMT of Breast Cancer Cells
-
In vitro and in vivo anti-primary effusion lymphoma activities of fuco...
-
Are seaweed-derived fucoidans possible future anti-cancer agents?
-
Fucoidan and Cancer: A Multifunctional Molecule with Anti-Tumor Potent...
-
Fucoidans Disrupt Adherence of Helicobacter pylori ...
-
Alginate Hydrogel Protects Encapsulated Hepatic HuH-7 Cells against He...
-
Pentosan polysulfate treatment ameliorates motor function with increas...
-
Sexual transmission of human T-cell lymphotropic virus type 1
-
Fucoidan Reduces Secretion and Expression of Vascular Endothelial Grow...
-
Controlling Seaweed Biology, Physiology and Metabolic Traits in Produc...
-
Cytotoxic Effects of Fucoidan Nanoparticles against Osteosarcoma
-
CSF CXCL10, CXCL9, and Neopterin as Candidate Prognostic Biomarkers fo...
-
Seaweed Antimicrobials: Isolation, Characterization, and Potential Use...
-
Lack of Recall Response to Tax in ATL and HAM/TSP Patients But Not in ...
-
Seaweed, Kelp, Bladderwrack ( Fucus vesiculosus ...
-
Antioxidant Marine Products in Cancer Chemoprevention
-
The pyrimidine analog FNC inhibits cell proliferation and viral protei...
-
Honokiol induces cell cycle arrest and apoptosis via inhibition of sur...
-
Seaweeds: A sustainable functional food for complementary and alternat...
-
Therapies from Fucoidan; Multifunctional Marine Polymers
Figures and tables
Figures & Media
Tables
View Options
View options
PDF/ePub
View PDF/ePubGet access
Access options
If you have access to journal content via a personal subscription, university, library, employer or society, select from the options below:
loading institutional access options
Alternatively, view purchase options below:
Access journal content via a DeepDyve subscription or find out more about this option.
